{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:00:20Z","timestamp":1775869220394,"version":"3.50.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Depression is one of the leading causes of avoidable suffering worldwide, and over 50% of patients do not respond to their first antidepressant treatment, which underscores the need for more effective alternatives. This clinical predicament urgently requires an effective solution. The core objective of this study is to clarify the clinical efficacy and application value of the triple reuptake inhibitor toludesvenlafaxine in patients with poor response to the first antidepressant therapy, providing a new basis for treatment options for this refractory group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This multicenter study included 61 patients meeting\n                      <jats:italic>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition<\/jats:italic>\n                      (\n                      <jats:italic>DSM-V<\/jats:italic>\n                      ) criteria for depression. All patients still had a Montgomery Depression Rating Scale (MADRS) score of \u226524 after 4 weeks of treatment with an adequate single initial antidepressant, and were clearly classified as an ineffective or partially effective initial antidepressant treatment. Patients were switched to toludesvenlafaxine for an 8-week treatment period. The primary outcome measure was the change in MADRS score from baseline to 8 weeks. The secondary outcome measures included the changes in the scores of the Hamilton Anxiety Scale (HAMA), the Dimensional Anhedonia Rating Scale (DARS), the Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF), and the Clinical Global Impression of Severity Scale (CGI-S) from baseline to 8 weeks.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      For such patients that did not respond to the first treatment, significant and rapid efficacy was demonstrated after switching to toludesvenlafaxine. At 8 weeks of treatment, the average MADRS score of the patients decreased by 15.5 points compared with the baseline (95% CI, \u221217.7 to \u221213.3;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001; Cohen\u2019s\n                      <jats:italic>d<\/jats:italic>\n                      = 2.35). Forty-three percent of them met the clinical remission, and 67% achieved a clinical response. More clinically significant is that the therapeutic effect emerged at an early stage\u20142 weeks (95% CI, \u22129.4 to \u22126.4;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001; Cohen\u2019s\n                      <jats:italic>d<\/jats:italic>\n                      = 1.52) and 4 weeks (95% CI, \u221213.3 to \u22129.8;\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.0001; Cohen\u2019s\n                      <jats:italic>d<\/jats:italic>\n                      = 2.11). After 2 weeks of treatment, there were statistically significant differences in the HAMA, Q-LES-Q-SF, and CGI-S scores at each time point compared with the baseline. The improvement in the DARS score was statistically significant from 4 weeks. In terms of safety, the most common adverse reactions were palpitations, constipation, nausea, vomiting, hypoesthesia, and dizziness, which are mostly mild to moderate and controllable. In particular, the drug significantly improved sexual dysfunction (95% CI, \u22124.3 to \u22120.7;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0071), which is crucial for improving treatment compliance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirmed that toludesvenlafaxine not only has significant clinical efficacy (including early onset, high remission, and response) for patients with depression who did not respond to the first antidepressant treatment, but also has good safety and can improve sexual dysfunction that affects compliance. This result highlights the significant position of toludesvenlafaxine in addressing the key clinical challenge of first treatment failure, providing a highly valuable new option for the subsequent treatment of such patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1740789","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:08:41Z","timestamp":1770282521000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in depression with ineffective or partially effective initial antidepressant treatment: a single-arm, multicenter clinical study"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingming","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Beijing Huilongguan Hospital, Peking University Huilongguan Clinical Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyan","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Beijing Huilongguan Hospital, Peking University Huilongguan Clinical Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Beijing Huilongguan Hospital, Peking University Huilongguan Clinical Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiye","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Beijing Changping Mental Health Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Psychology, Tianjin Anding Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Psychology, Tianjin Anding Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Psychology, Tianjin Anding Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Hebei Provincial Mental Health Center, The Sixth Clinical Medical College of Hebei University","place":["Baoding, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoping","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Hebei Provincial Mental Health Center, The Sixth Clinical Medical College of Hebei University","place":["Baoding, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keqing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Hebei Provincial Mental Health Center, The Sixth Clinical Medical College of Hebei University","place":["Baoding, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Psychology, Tianjin Anding Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fude","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Beijing Huilongguan Hospital, Peking University Huilongguan Clinical Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)02141-3","article-title":"Time for united action on depression:a Lancet-World Psychiatric Association Commission","volume":"399","author":"Herrman","year":"2022","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1394787","article-title":"Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review","volume":"15","author":"Di Vincenzo","year":"2024","journal-title":"Front Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2025.1642605","article-title":"Glymphatic system and psychiatric disorders: need for a new paradigm","volume":"16","author":"Barlattani","year":"2025","journal-title":"Front Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-32-9271-0_10","article-title":"Standardized treatment strategy for depressive disorder","volume":"1180","author":"Wang","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7370.934","article-title":"Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care","volume":"325","author":"Rost","year":"2002","journal-title":"BMJ"},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biopsych.2004.04.005","article-title":"One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies","volume":"56","author":"Rush","year":"2004","journal-title":"Biol Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2017.08.019","article-title":"Treatment resistant depression:a multi-scale, systems biology approach","volume":"84","author":"Akil","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/YIC.0000000000000196","article-title":"Antidepressant combination versus antidepressants plus second-generation anti-psychotic augmentation in treatment-resistant unipolar depression","volume":"33","author":"Gobbi","year":"2018","journal-title":"Int Clin Psychopharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-014-0171-5","article-title":"Early Switching Strategies in Antidepressant Non-Responders: current evidence and future research directions","volume":"28","author":"Kudlow","year":"2014","journal-title":"CNS Drugs"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/0897190012467210","article-title":"Guidance for the discontinuation or switching of antidepressant therapies in adults","volume":"26","author":"Ogle","year":"2013","journal-title":"J Pharm Pract"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.16r10749","article-title":"Switching the Antidepressant after non-response in adults with major depression:a systematic literature search and meta-analysis","volume":"79","author":"Bschor","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"B13","article-title":"Watchful waiting when treating depression:Still our maxim","volume":"15","author":"Hofmann","year":"2014","journal-title":"J fur Neurologie Neurochirurgie und Psychiatr"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2019.04.104","article-title":"Guidelines for the diagnosis and treatment of depressive disorders in China:the second edition","volume":"253","author":"Feng","year":"2019","journal-title":"J Affect Disorder"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/0004867420979353","article-title":"The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders","volume":"55","author":"Malhi","year":"2021","journal-title":"Aust NZJ Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"01557","DOI":"10.1136\/bmj.o1557","article-title":"Management of depression in adults:summary of updated NICE guidance","volume":"378","author":"Kendrick","year":"2022","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2174\/0118715273357909241126064951","article-title":"The potential role of dopamine pathways in the pathophysiology of depression: current advances and future aspects","volume":"24","author":"Pannu","year":"2025","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.o1557","article-title":"Treatment-resisitant depression in primary care a across Canada","volume":"56","author":"Rizvi","year":"2014","journal-title":"Can J Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J Affect Disord"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115378","article-title":"Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)","volume":"327","author":"Pettorruso","year":"2023","journal-title":"Psychiatry Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15040161","article-title":"Patient experience with intranasal esketamine in treatment-resistant depression: insights from a multicentric Italian study (REAL-ESKperience)","volume":"15","author":"Di Nicola","year":"2025","journal-title":"J Pers Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01827","article-title":"Triple reuptake inhibitors as potential therapeutics for depression and other disorders: design paradigm and developmental challenges","volume":"61","author":"Subbaiah","year":"2018","journal-title":"J Med Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.741794","article-title":"Pharmacological Characterization of toludesvenlafaxine as a triple reuptake Inhibitor","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003138","article-title":"Efficacy and dose-response relationships of antidepressants in the acute treatment of major depressive disorders: a systematic review and network meta-analysis","volume":"138","author":"Zhou","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41398-023-02435-0","article-title":"A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of toludesvenlafaxine (LY03005) for major depressive disorder","volume":"13","author":"Mi","year":"2023","journal-title":"Transl Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/acps.12122","article-title":"Pharmacological management of unipolar depression","volume":"443","author":"Malhi","year":"2013","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2015.07.062","article-title":"Development and validation of the Dimensional Anhedonia Rating Scale (DARS) in a community sample and individuals with major depression","volume":"229","author":"Rizvi","year":"2015","journal-title":"Psychiatry Res"},{"key":"B30","article-title":"Quality of Life Enjoyment and Satisfaction Questionnaire:a new measure","volume":"29","author":"Endicott","year":"1993","journal-title":"Psychopharmacol Bull"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-7-7","article-title":"The improved Clinical Global Impression Scale (iCGI): development and validation in depression","volume":"6","author":"Kadouri","year":"2007","journal-title":"BMC Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/009262300278623","article-title":"The Arizona sexual experience scale (ASEX): reliability and validity","volume":"26","author":"MeGahuey","year":"2000","journal-title":"Sex Marital Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0071-0","article-title":"Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders:rationale and current status of research","volume":"27","author":"Celada","year":"2013","journal-title":"CNS Drugs"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.10.008","article-title":"Predictors of treatment outcome in depression in later life:A systematic review and meta-analysis","volume":"227","author":"Tunvirachaisakul","year":"2018","journal-title":"J Affect Disord"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eurpsy.2017.02.485","article-title":"Anhedonia predicts poor psychosocial functioning:Results from a large cohort of patients treated for major depressive disorder by general practitioners","volume":"44","author":"Vinckier","year":"2017","journal-title":"Eur Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3949\/ccjm.75.1.57","article-title":"The STAR*D study: treating depression in the real world","volume":"75","author":"Gaynes","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-007-0061-3","article-title":"The STAR*D Project results: a comprehensive review of findings","volume":"9","author":"Warden","year":"2007","journal-title":"Curr Psychiatry Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14345","article-title":"Efficacy and safety of AXS-05 (Dextromethorphan-bupropion) in patients with major depressive disorder: A phase 3 randomized clinical trial (GEMINI)","volume":"83","author":"Iosifescu","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.12.147","article-title":"The impact of early remission on disease trajectory and patient outcomes in major depression disorder (MDD): A targeted literature review and microsimulation modeling approach based on the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study","volume":"325","author":"Arnaud","year":"2023","journal-title":"J Affect Disord"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06700-2","article-title":"PET\/CT study of dopamine transporter (DAT) binding with the triple reuptake inhibitor toludesvenlafaxine in rats and humans","volume":"51","author":"Huang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1194090","article-title":"Potential efficacy of dopaminergic antidepressants in treatment resistant anergic-anhedonic depression results of the chronic anergic-anhedonic depression open trial-CADOT","volume":"14","author":"Dormegny-Jeanjean","year":"2023","journal-title":"Front Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710000076","article-title":"Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons","volume":"14","author":"Guiard","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.12.002","article-title":"Depression and antidepressants:insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters","volume":"129","author":"Britta","year":"2011","journal-title":"Pharmacol Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/YCO.0000000000000903","article-title":"New trends in personalized treatment of depression","volume":"37","author":"Sampogna","year":"2024","journal-title":"Curr Opin Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1740789\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:54:10Z","timestamp":1771926850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1740789\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":46,"alternative-id":["10.3389\/fpsyt.2025.1740789"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1740789","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"article-number":"1740789"}}